Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
about
NATH, a novel gene overexpressed in papillary thyroid carcinomasTumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesisSpotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesSelective use of sorafenib in the treatment of thyroid cancerMolecular Targeted Therapies of Aggressive Thyroid CancerMultikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinibTreatment strategies for radioactive iodine-refractory differentiated thyroid cancerProgress in molecular-based management of differentiated thyroid cancerOverview and management of dermatologic events associated with targeted therapies for medullary thyroid cancerPhase II clinical trial of sorafenib in metastatic medullary thyroid cancerThe enigmatic role of angiopoietin-1 in tumor angiogenesisVascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomasUp-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathwayA phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaHypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemiaHepatic expression of ANG2 RNA in metastatic colorectal cancer.Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.HiSStology: high spectral and spatial resolution magnetic resonance imaging detection of vasculature validated by histology and micro-computed tomographyVandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancerSlit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathwayMolecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancersA phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.Lymphatic vessels as targets of tumor therapy?Lymphatic function, lymphangiogenesis, and cancer metastasis.Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.New therapeutic approaches to treat medullary thyroid carcinoma.A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.Medullary thyroid carcinoma: molecular signaling pathways and emerging therapiesLymphatic vessel activation in cancer.Hypoxia-inducible factor in thyroid carcinomaNew therapies for dedifferentiated papillary thyroid cancerExpression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.The fibroblast: sentinel cell and local immune modulator in tumor tissue.Not just angiogenesis--wider roles for the angiopoietins.Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.Crosstalk between angiogenesis and lymphangiogenesis in tumor progression.Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma
P2860
Q24302202-534A2B7E-476C-46DD-B97F-48AEEDB7D365Q24669710-DE534E28-A227-4CCF-B685-986E51B08E70Q26751274-A280435E-8604-4A84-85FC-F86837D1589BQ26752891-D2521B89-CCE2-4AC6-8772-8E9DC9E7CC69Q26774734-BE2448D8-DAAC-4AFD-9A06-8A4444EFBB28Q26821959-930F76C9-A833-4604-8BFE-EF6E4EE987D0Q26862841-826EB3E3-FA50-4C89-9688-B304517596B9Q26999887-4A3E62AB-7C83-4888-AC36-6FC4370F9325Q27005701-3F49DDE7-70D8-46CB-840C-D309C5CE4041Q27851560-45DD42E9-06BB-4096-8A2B-FE888251CC07Q28191178-0DC1E266-96DE-4C37-AD9F-34E2AD6E4E78Q28200101-02DD24E6-A3C2-4946-BDDE-8F21B1698C58Q28211085-09D36C58-FA2F-4F28-8D43-1A29B632417AQ28216853-15F68010-3319-4A12-849B-E948BA1DB17FQ28304566-D4625182-B776-4F2C-84E0-E6C3FA272FAAQ28344343-456C0DFF-EB12-43B3-924B-F5E27A8DDD10Q33197535-F6D7AF0B-39B7-40B1-92CB-238F2D5DB05AQ33245035-6CB0769B-0284-4276-A951-FC5077408B94Q33710562-23F30F44-6245-40FD-A82C-0923128DB04FQ33857065-2EC02998-F52F-48EC-A402-4F1108108B47Q33984845-4F0BC869-2366-4DE3-9898-A37DC74D32F9Q34003819-82D8653B-9BCA-4503-9BD1-BC1DCAF6BA90Q34123724-D04ED547-AC9C-4F44-8A15-795A1C9CD1B8Q34330748-94F12EF6-FAC3-41B4-A556-B9DBB64ADEA5Q34372169-9D94BB37-135D-4A90-9F0E-0DBF8AC377D5Q34398724-AB51366C-D512-4D04-BF18-D22905CF1813Q34678882-2218C7A4-05B0-48D2-97F9-5E48C5E41A6DQ34726233-43E02E45-1416-489F-8E69-F2CD67697964Q34956830-6368D3A7-5B10-44DE-923E-4B749B529907Q35038893-E0C56779-875A-4D9B-BA5F-5B5FD3C59A7BQ35051498-70761810-3E7D-4BD8-A073-8BB0913D9D44Q35099457-D8A38001-4F96-47F1-816A-877A86972B96Q35381593-43D53767-1973-4C01-A7A5-4E064C4D09D4Q35587630-457071ED-5F06-4689-B4F5-18645E183503Q35593451-19011219-B0C6-4CAA-942A-B6B27E8402A9Q35597377-0B7650DF-7559-471F-B687-38CA2EA5068BQ35604097-048272F2-DADA-496B-85DB-55268DA7E761Q35730252-D84E3461-2F0B-4497-8ABA-AFA98310660DQ35746653-7656CF6A-6BCF-439C-AE67-499B4E10481EQ35746804-9AB8CD0C-3997-442F-8553-1BC1E4CE32ED
P2860
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Expression of angiogenesis sti ...... linical pathological features.
@ast
Expression of angiogenesis sti ...... linical pathological features.
@en
type
label
Expression of angiogenesis sti ...... linical pathological features.
@ast
Expression of angiogenesis sti ...... linical pathological features.
@en
prefLabel
Expression of angiogenesis sti ...... linical pathological features.
@ast
Expression of angiogenesis sti ...... linical pathological features.
@en
P2093
P2860
P1476
Expression of angiogenesis sti ...... linical pathological features.
@en
P2093
I Bongarzone
M A Pierotti
P2860
P304
P356
10.1016/S0002-9440(10)65515-0
P407
P577
1999-12-01T00:00:00Z